Obesity Pharmacotherapy

Obesity Pharmacotherapy

Obesity pharmacotherapy means using approved medicines to achieve clinically meaningful weight loss in people for whom lifestyle changes alone have not been enough. Current guidelines generally recommend medication for adults with a body mass index of 30 kg/m² or more, or 27 kg/m² or more with at least one weight-related condition such as type 2 diabetes, hypertension or abnormal lipids. Drug treatment for obesity has changed a great deal over the past decade. Older brain-acting appetite suppressants, with limited efficacy and safety concerns, have given way to incretin-based drugs that have reset expectations for how much weight can be lost.

Today’s obesity drugs fall into several classes by mechanism. GLP-1 receptor agonists such as semaglutide have produced weight reductions of about 15% to 17% of body weight in pivotal trials, setting a new standard of care. Dual and triple receptor agonists go further, with newer drugs producing weight loss approaching or exceeding bariatric surgery. Beyond weight, modern obesity drugs are judged on how well they improve cardiometabolic risk factors, reduce obesity-related conditions and keep their benefits over long treatment periods.

Clinical Relevance to Retatrutide

Retatrutide could be a step forward in obesity drug treatment. Phase 2 trial data showed mean weight reductions of up to 24.2% at the highest dose over 48 weeks. Phase 3 trials have since reported larger reductions (-28.3% at 12 mg over 80 weeks in TRIUMPH-1), which would place retatrutide among the most effective non-surgical obesity treatments if approved. Its triple-agonist action explains the extra weight loss: it curbs appetite, improves insulin sensitivity and raises energy use, tackling several drivers of obesity at once. Retatrutide is not approved; Lilly says it plans to file for approval no later than the first quarter of 2027.